DILH
ALDR

Dai-ichi Life Holdings’s Alder Biopharmaceuticals ALDR Stock Holding History

Dai-ichi Life Holdings’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-37,623
Closed -$1.23M – 517
2016
Q3 		$1.23M Buy
37,623
+9,261
+33% +$282K 0.04% 379
2016
Q2 		$708K Buy
+28,362
New +$767K 0.02% 414

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Dai-ichi Life Holdings's ALDR Position: Q4 2016 in Review

Dai-ichi Life Holdings sold out of Alder Biopharmaceuticals (ALDR) in Q4 2016, closing a stake of 37,623 shares — an estimated $1.23M sold.

Dai-ichi Life Holdings first reported a position in ALDR in Q2 2016 and held it in 2 quarters. The position peaked at $1.23M in Q3 2016. 145 funds tracked by Wall St. Rank hold ALDR as of Q4 2016.

  • Dai-ichi Life Holdings reported no remaining Alder Biopharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Dai-ichi Life Holdings sold 37,623 Alder Biopharmaceuticals shares in Q4 2016, an estimated $1.23M.
  • Dai-ichi Life Holdings first reported a position in Alder Biopharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Dai-ichi Life Holdings's Alder Biopharmaceuticals position peaked at $1.23M in Q3 2016.
  • 145 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2016.

Based on Dai-ichi Life Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.